Neil Palmisiano was named the new deputy director of phase I therapeutics for hematologic malignancies and co-medical director of the Office of Human Research Services at Rutgers Cancer Institute; and new system leader for Leukemia for RWJBarnabas Health.
More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
